Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis

Area of Science:

• Cell Biology
• Molecular Biology
• Oncology

Background:

• Apo2 ligand (Apo2L/TRAIL) is a TNF cytokine family member inducing apoptosis in cancer cells.
• Its presence in normal tissues suggests physiological roles.
• Understanding Apo2L/TRAIL interactions in bone cells is crucial for therapeutic applications.

Purpose of the Study:

• Investigate Apo2L/TRAIL and its receptor expression in human normal osteoblast-like cells (NHBC).
• Assess Apo2L/TRAIL's efficacy in inducing apoptosis in NHBC and osteogenic sarcoma cells.
• Determine the role of decoy receptors in NHBC resistance to Apo2L/TRAIL.

Main Methods:

• mRNA expression analysis of Apo2L/TRAIL, DR4, DR5, DcR-1, DcR-2, and OPG in NHBC.
• Immunofluorescence staining for protein localization of Apo2L/TRAIL, OPG, DR5, DcR-1, and DcR-2.
• Cell death assays (morphological, caspase-3 activation) on NHBC and osteogenic sarcoma cells treated with Apo2L/TRAIL and chemotherapeutics.

Main Results:

• NHBC expressed abundant mRNA for Apo2L/TRAIL, death, and decoy receptors.
• Apo2L/TRAIL protein was cytoplasmic in NHBC; OPG was cell surface-expressed.
• NHBC resisted Apo2L/TRAIL-induced apoptosis, unlike sensitive osteogenic sarcoma cells, due to high decoy receptor expression.

Conclusions:

• NHBC resist Apo2L/TRAIL-mediated apoptosis via a balance of pro-survival and pro-apoptotic molecules.
• Osteogenic sarcoma cells exhibit low decoy receptor levels, rendering them sensitive to Apo2L/TRAIL.
• Apo2L/TRAIL therapy, combined with chemotherapy, may have limited toxicity to normal osteoblasts in treating skeletal malignancies.